Matches in SemOpenAlex for { <https://semopenalex.org/work/W2598135337> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2598135337 abstract "510 Background: Hormone resistance is linked in part to cross-talk between ER signalling and PI3K/Akt/mTOR pathway. Following results of the BOLERO-2 trial, everolimus (E), a potent mTOR inhibitor, has recently been approved in combination with exemestane in women with HR+ MBC refractory to aromatase inhibitor (AI). However, E is frequently associated with specific toxicities, and predictive markers of efficacy are needed. We report here the final results of translational studies within the TAMRAD randomized Phase II trial, comparing tamoxifen (TAM) to TAM+E in AI pre-treated MBC. Methods: Tumor samples from 51 patients among the 111 treated in the TAMRAD trial were retrieved. Hot spot mutations of PI3K (exon 9-20), and KRAS (exon 2) were described. TMA analysis evaluated IHC expression of PTEN, pAkt, PI3K, LKB1, S6K, pS6K, 4EBP1, p4EBP1, and eIF4E. Exploratory analysis of E efficacy in each biomarker subgroup (high vs low expression defined by median percentage of marked cells) was done. Results: Patients characteristics and treatment efficacy among this sub-population were similar to the results from the whole population: Time to progression was 10 months for the TAM+E treated patients vs. 5.5 months for the TAM treated patients, HR: 0.59 (95% CI 0.33-1.07). PI3K-Akt pathway: All patients derived benefit from E regardless of PI3K mutational status, PTEN or pAkt expression. Surprisingly, E efficacy was greater in patients with low PI3K expression (n=12, HR=0.11, 95%CI 0.01-0.96) than in patients with high PI3K expression (n= 28, HR=0.9; 95%CI 0.49-2.41) PI3K independent pathway: Patients with low expression of the anti-oncogene LKB1 derived greater benefit from E (n=22, HR=0.33; 95%CI 0.13-0.89) than patients with high LKB1 expression (n=25, HR=0.75; 95%CI 0.32-1.74) mTOR downstream effectors: Patients with high p4EBP1 (n=27, HR=0.37; 95%CI 0.15-0.90) or low 4EBP1 (n=21, HR=0.39; 95%CI 0.14-1.08) were the subgroups most likely to benefit from E. Conclusions: Those results are in favor of a better efficacy of E for patients with PI3K independent activation of mTOR. If confirmed, they could have important implications for future patient selection. Clinical trial information: NCT01298713." @default.
- W2598135337 created "2017-04-07" @default.
- W2598135337 creator A5032686530 @default.
- W2598135337 creator A5035139653 @default.
- W2598135337 creator A5038384830 @default.
- W2598135337 creator A5041410352 @default.
- W2598135337 creator A5049369439 @default.
- W2598135337 creator A5055326442 @default.
- W2598135337 creator A5073063132 @default.
- W2598135337 creator A5074178269 @default.
- W2598135337 creator A5075436616 @default.
- W2598135337 creator A5079971350 @default.
- W2598135337 creator A5086379442 @default.
- W2598135337 date "2013-05-20" @default.
- W2598135337 modified "2023-09-29" @default.
- W2598135337 title "Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): Final results of the TAMRAD trial translational study." @default.
- W2598135337 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.510" @default.
- W2598135337 hasPublicationYear "2013" @default.
- W2598135337 type Work @default.
- W2598135337 sameAs 2598135337 @default.
- W2598135337 citedByCount "12" @default.
- W2598135337 countsByYear W25981353372013 @default.
- W2598135337 countsByYear W25981353372014 @default.
- W2598135337 countsByYear W25981353372015 @default.
- W2598135337 countsByYear W25981353372016 @default.
- W2598135337 crossrefType "journal-article" @default.
- W2598135337 hasAuthorship W2598135337A5032686530 @default.
- W2598135337 hasAuthorship W2598135337A5035139653 @default.
- W2598135337 hasAuthorship W2598135337A5038384830 @default.
- W2598135337 hasAuthorship W2598135337A5041410352 @default.
- W2598135337 hasAuthorship W2598135337A5049369439 @default.
- W2598135337 hasAuthorship W2598135337A5055326442 @default.
- W2598135337 hasAuthorship W2598135337A5073063132 @default.
- W2598135337 hasAuthorship W2598135337A5074178269 @default.
- W2598135337 hasAuthorship W2598135337A5075436616 @default.
- W2598135337 hasAuthorship W2598135337A5079971350 @default.
- W2598135337 hasAuthorship W2598135337A5086379442 @default.
- W2598135337 hasConcept C121608353 @default.
- W2598135337 hasConcept C126322002 @default.
- W2598135337 hasConcept C143998085 @default.
- W2598135337 hasConcept C23589133 @default.
- W2598135337 hasConcept C2775930923 @default.
- W2598135337 hasConcept C2779699572 @default.
- W2598135337 hasConcept C29456083 @default.
- W2598135337 hasConcept C502942594 @default.
- W2598135337 hasConcept C530470458 @default.
- W2598135337 hasConcept C71924100 @default.
- W2598135337 hasConceptScore W2598135337C121608353 @default.
- W2598135337 hasConceptScore W2598135337C126322002 @default.
- W2598135337 hasConceptScore W2598135337C143998085 @default.
- W2598135337 hasConceptScore W2598135337C23589133 @default.
- W2598135337 hasConceptScore W2598135337C2775930923 @default.
- W2598135337 hasConceptScore W2598135337C2779699572 @default.
- W2598135337 hasConceptScore W2598135337C29456083 @default.
- W2598135337 hasConceptScore W2598135337C502942594 @default.
- W2598135337 hasConceptScore W2598135337C530470458 @default.
- W2598135337 hasConceptScore W2598135337C71924100 @default.
- W2598135337 hasLocation W25981353371 @default.
- W2598135337 hasOpenAccess W2598135337 @default.
- W2598135337 hasPrimaryLocation W25981353371 @default.
- W2598135337 hasRelatedWork W1867192432 @default.
- W2598135337 hasRelatedWork W1990883066 @default.
- W2598135337 hasRelatedWork W2020372547 @default.
- W2598135337 hasRelatedWork W2077252057 @default.
- W2598135337 hasRelatedWork W2096283457 @default.
- W2598135337 hasRelatedWork W2106036365 @default.
- W2598135337 hasRelatedWork W2111945133 @default.
- W2598135337 hasRelatedWork W2113458582 @default.
- W2598135337 hasRelatedWork W2153061474 @default.
- W2598135337 hasRelatedWork W2167188058 @default.
- W2598135337 hasRelatedWork W2313394748 @default.
- W2598135337 hasRelatedWork W2528213995 @default.
- W2598135337 hasRelatedWork W2561564946 @default.
- W2598135337 hasRelatedWork W2703016114 @default.
- W2598135337 hasRelatedWork W2756316276 @default.
- W2598135337 hasRelatedWork W2906483843 @default.
- W2598135337 hasRelatedWork W2965552450 @default.
- W2598135337 hasRelatedWork W3011736856 @default.
- W2598135337 hasRelatedWork W3014181425 @default.
- W2598135337 hasRelatedWork W3167238031 @default.
- W2598135337 isParatext "false" @default.
- W2598135337 isRetracted "false" @default.
- W2598135337 magId "2598135337" @default.
- W2598135337 workType "article" @default.